PTGER4 and myeloid sarcoma: MS risk variants have been discovered in PTGER4 non-coding gene regions, indicating that these risk variants are potentially detrimental to regulation of its expression [11]; in fact, a downregulated PTGER4 expression has been observed in MS patients’ blood cells compared to healthy controls [57].